Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Everest MedicinesSTU:6HN -1.43%43 PS Ratio is 4.55 as of Aug. 07, 2026, which is 90% below its 10-year median of 44.02. GuruFocus rates STU:6HN with a GF Score™ of 43/100 and a GF Value™ of €31.47. The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Everest Medicines ranks better than 67.06% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Everest Medicines's share price is €2.76.
Everest Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.61. Hence, Everest Medicines's PS Ratio for today is 4.55.
The historical rank and industry rank for Everest Medicines's PS Ratio or its related term are showing as below:
STU:6HN'
s PS Ratio Range Over the Past 10 Years
Min: 4.13 Med: 44.02 Max: 575
Current: 4.93
During the past 8 years, Everest Medicines's highest PS Ratio was 575.00. The lowest was 4.13. And the median was 44.02.
STU:6HN's PS Ratio is ranked better than 67.06% of 929
companies
in the Biotechnology industry
Industry Median: 9.49
vs STU:6HN: 4.93
During the past 8 years, Everest Medicines's highest 3-Year average Revenue per Share Growth Rate was 388.70% per year. The lowest was 388.70% per year. And the median was 388.70% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Everest Medicines PS Ratio Related Terms
Everest Medicines PS Ratio Historical Data
* Premium members only.
The historical data trend for Everest Medicines's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Everest Medicines's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's PS Ratio distribution charts can be found below:
* The bar in red indicates where Everest Medicines's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Everest Medicines's Share Price of today is €2.76.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.61.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Everest Medicines (STU:6HN) has a PS Ratio of 4.55 as of Aug. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Everest Medicines and its competitors. This is 90% below median its historical median of 44.02. Over the past decade, Everest Medicines' PS Ratio has ranged from 4.13 to 575.00. According to the industry distribution chart, Everest Medicines ranks #306 out of 929 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Everest Medicines' PS Ratio too high?
Everest Medicines' current PS Ratio of 4.55 is 90% below median its 10-year median of 44.02. Over the past 10 years, this metric has ranged from a low of 4.13 to a high of 575.00. The Biotechnology industry median PS Ratio is 9.49. Everest Medicines' value of 4.55 is 52.1% below this industry median. Based on the distribution chart, Everest Medicines ranks #306 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Everest Medicines has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #306 out of 929 companies for PS Ratio. This puts Everest Medicines in the upper half of its industry. The industry median PS Ratio is 9.49. Everest Medicines' value of 4.55 is 52.1% below this benchmark. Historically, Everest Medicines' own PS Ratio has ranged from 4.13 to 575.00 over the past decade. While the company's 10-year median is 44.02 vs. the industry median of 9.49, Everest Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Everest Medicines's current PS Ratio of 4.55 is 52.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Everest Medicines and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Medicines's current PS Ratio is 4.55, which is 90% below median its own 10-year median of 44.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Everest Medicines (STU:6HN) has a current PS Ratio of 4.55. The stock's GF Value™ is €31.47, compared to a current price of €2.76 — trading 91.2% below its estimated fair value. The current PS Ratio is 4.55, which is 90% below median its 10-year median of 44.02 and 52.1% below the Biotechnology industry median of 9.49. Everest Medicines' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Everest Medicines (STU:6HN), the current PS Ratio is 4.55 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (STU:6HN) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of €2.76 is trading 91.2% below its estimated GF Value™ of €31.47.
Key valuation signals for STU:6HN:
PS Ratio: 4.55 (90% below median its 10-year median of 44.02)
GF Value™: €31.47 vs. price of €2.76 (91.2% below fair value)
Industry Position: 52.1% below the Biotechnology median (#306 of 929)
No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
43GF Score
Get the complete analysis for STU:6HN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6HN has been successfully added to your 
